A panelist discusses how emerging investigational agents for NMIBC show promise through diverse mechanisms, including oncolytic viruses (CG0070), immune checkpoint inhibitors (durvalumab, sasanlimab), ...

"Studying the microbiome overall is challenging because it's dirty science. You have to be incredibly careful with contamination," says Ilaha Isali, MD, MSc, and Laura Bukavina, MD, MPH, MSc. Isali: ...

“Another aspect is how to make this more and more complex diagnostic chain for prostate cancer work in practice, because we now have so [many] more tools than we had a decade ago,” says Tobias ...

VIR-5500 demonstrated promising PSA response in mCRPC patients, with 58% achieving at least a 50% reduction in PSA levels. No dose-limiting toxicities were observed, and treatment-emergent adverse ...

"If we synergize our efforts and our energy, as the level of the sea rises, all ships on the sea will rise with it," says Wayne Kuang, MD. In this video, Wayne Kuang, MD, discusses the importance of ...

Erdafitinib received full FDA approval for FGFR3-positive urothelial carcinoma, demonstrating improved overall survival in the phase 3 THOR trial. Cefepime ...

Please review the standard treatment options (intravesical chemotherapy, PD-L1 inhibitors, other immunotherapeutic options) currently available for patients with BCG-unresponsive NMIBC.

“The key take home message of that study was that having assumptions about basic medical terminology that we think are simple may actually leave patients confused,” says Vikram M. Narayan, MD. In this ...

"The interplay between the microbiome and bladder cancer is very complex," says Ilaha Isali, MD, MSc. Isali: The interplay between the microbiome and bladder cancer is very complex. There is still ...

Disitamab vedotin and toripalimab-tpzi combination shows high efficacy in locally advanced/metastatic urothelial carcinoma, with a 73.2% objective response rate and 90.2% disease control rate. The ...

Would you please start by giving a brief overview of BCG-unresponsive NMIBC? Nonmuscle Invasive Bladder Cancer Prior to recent therapeutic innovations in the bladder space what challenges or unmet ...

Enfortumab vedotin and pembrolizumab combination significantly improves overall and progression-free survival in advanced urothelial carcinoma compared to platinum-based chemotherapy. The EV-302 trial ...